CGT

1,155개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,155 programs
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR30 (4SCAR19 and 4SCAR30)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR38 (4SCAR19 and 4SCAR38)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR70 (4SCAR19 and 4SCAR70)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 2

8/12-Day Production of Car-T Cells (8/12-Day Production of Car-T Cells)

Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) · Non Hodgkin Lymphoma (NHL)

#NonHodgkinLymphomaNHL#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 2

8/12-Day Production of Cryopreserved Car-T Cells (8/12-Day Production of Cryopreserved Car-T Cells)

Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) · Non Hodgkin Lymphoma (NHL)

#NonHodgkinLymphomaNHL#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

A-CAR028 (A-CAR028)

Acute Myeloid Leukemia (AML); CAR-T Cell Therapy · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx UK II LtdPreclinical

AAV OPTIRPE65 (AAV OPTIRPE65)

Leber Congenital Amaurosis (LCA); Eye Diseases · Leber Congenital Amaurosis (LCA)

#LeberCongenitalAmaurosisLCA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleREGENXBIO Inc.Phase 2

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

Homozygous Familial Hypercholesterolemia (HoFH) · Homozygous Familial Hypercholesterolemia

#HomozygousFamilialHypercholester#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV-GAD High Dose (AAV-GAD High Dose)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleUniversity of OxfordPhase 2

AAV-mediated REP1 gene replacement (AAV-mediated REP1 gene replacement)

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTAAVLimited DatastaleMark TuszynskiPhase 1

AAV2-BDNF Gene Therapy (AAV2-BDNF Gene Therapy)

Alzheimer's Disease; Mild Cognitive Impairment · Alzheimer's Disease

#AlzheimersDisease#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 (AAV2-hAQP1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 1 (AAV2-hAQP1 Concentration 1)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 2 (AAV2-hAQP1 Concentration 2)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 3 (AAV2-hAQP1 Concentration 3)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx, LLCPhase 2

AAV2-hAQP1 Concentration 4 (AAV2-hAQP1 Concentration 4)

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Paroti… · Grade 2 and 3 Late Xerostomia Caused by

#Grade2and3LateXerostomiaCausedby#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleSpark Therapeutics, Inc.Phase 2

AAV2-hCHM (AAV2-hCHM)

Choroideremia; CHM (Choroideremia) Gene Mutations · Choroideremia

#Choroideremia#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleGenentech, Inc.Preclinical

AAV2-hRPE65v2 (AAV2-hRPE65v2)

Inherited Retinal Dystrophy Due to RPE65 Mutations · Multi-target

#Multi-target#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTAAVLimited DatastaleGenzyme, a Sanofi CompanyPhase 1

AAV2-sFLT01 (AAV2-sFLT01)

Macular Degeneration; Age-Related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleeyeDNA TherapeuticsPhase 2

AAV2/5-hPDE6B (AAV2/5-hPDE6B)

Retinitis Pigmentosa · Retinitis Pigmentosa

#RetinitisPigmentosa#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued

21 / 58 pages

← PreviousNext →